https://www.selleckchem.com/peptide/pmx-205.html
Inhibitors of endocannabinoid membrane transport and hydrolysis yield mixed results. In targeting the endocannabinoid system for developing new treatments for drug addiction, future research should focus on 'neutral' CB1 receptor antagonists and CB2 receptor agonists. Such compounds may offer a well-tolerated pharmacological profile and curb addiction by preventing drug-seeking triggered by conditioned contextual cues.Intravenous drug self-administration remains the 'gold standard' for assessing abuse liability. Failure of a drug to main
Like
Comment
Share
